Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials

被引：0
|
作者：
I. Dicembrini
S. Giannini
B. Ragghianti
E. Mannucci
M. Monami
机构：
[1] Diabetology,
[2] Azienda Ospedaliero-Universitaria Careggi and University of Florence,undefined
来源：
Journal of Endocrinological Investigation | 2019年 / 42卷
关键词：
PCSK-9 inhibitors; Major cardiovascular events; Mortality; LDL cholesterol; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1029 / 1039
页数：10
相关论文
共 50 条
  • [1] Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials
    Dicembrini, I.
    Giannini, S.
    Ragghianti, B.
    Mannucci, E.
    Monami, M.
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2019, 42 (09) : 1029 - 1039
  • [2] Longer-term impact of PCSK9 inhibitors on major adverse cardiovascular events and all-cause mortality: a systematic review and meta-analysis of randomised controlled trials
    Grover, J.
    Yao, W. X.
    Amarasekera, A. T.
    Leung, A. N. W.
    Sekhar, P.
    Tan, T. C.
    [J]. EUROPEAN HEART JOURNAL, 2023, 44
  • [3] LDL-CHOLESTEROL REDUCTION WITH PCSK9 INHIBITORS: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS
    Casula, Manuela
    Scotti, Lorenza
    Bernocchi, Ottavia
    Galimberti, Federica
    Tragni, Elena
    Corrao, Giovanni
    Catapano, Alberico Luigi
    [J]. ATHEROSCLEROSIS, 2017, 263 : E244 - E244
  • [4] Selenium, antioxidants, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials
    Jenkins, David J. A.
    Kitts, David
    Giovannucci, Edward L.
    Sahye-Pudaruth, Sandhya
    Paquette, Melanie
    Mejia, Sonia Blanco
    Patel, Darshna
    Kavanagh, Meaghan
    Tsirakis, Tom
    Kendall, Cyril W. C.
    Pichika, Sathish C.
    Sievenpiper, John L.
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 2020, 112 (06): : 1642 - 1652
  • [5] CIRCULATING PCSK9 IS NOT ASSOCIATED WITH ALL-CAUSE AND CARDIOVASCULAR MORTALITY
    Silbernagel, Guenther
    Scharnagl, Hubert
    Kleber, Marcus
    Stojakovic, Tatjana
    Maerz, Winfried
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 1662 - 1662
  • [6] PCSK9 Inhibitors Modify Plaque and Reduce Plaque Progression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Lima, Ana E.
    Boas, Gustavo Vilas
    Ferreira, Andre L. Carvalho
    Gonzalez, Maria Benitez
    Guida, Camila
    [J]. CIRCULATION, 2023, 148
  • [7] Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials
    Casula, Manuela
    Olmastroni, Elena
    Boccalari, Mezio T.
    Tragni, Elena
    Pirillo, Angela
    Catapano, Alberico L.
    [J]. PHARMACOLOGICAL RESEARCH, 2019, 143 : 143 - 150
  • [8] The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials
    Imbalzano, Egidio
    Ilardi, Federica
    Orlando, Luana
    Pintaudi, Basilio
    Savarese, Gianluigi
    Rosano, Giuseppe
    [J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2023, 9 (04) : 318 - 327
  • [9] Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials
    Eraikhuemen, Nathaniel
    Leung, Simon
    Warren, Shalonda Barnes
    Lazaridis, Dovena
    Smith, Carla Hawkins
    Kearson, Margaretta L.
    Marcellus, Valerie
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2023, 23 (02) : 113 - 126
  • [10] ASPIRIN FOR PRIMARY PREVENTION OF CARDIOVASCULAR AND ALL-CAUSE MORTALITY: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Alrifai, A.
    Al Halabi, S.
    Rosenstein, R. S.
    [J]. CARDIOLOGY, 2015, 131 : 93 - 93
12345